久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國人類基因組科學公司（Human Genome Sciences, Inc.）
人類基因組科學公司，簡稱HGSI，是一個開發(fā)以新蛋白質和基因為主的生技藥物新興公司。 HGS公司成立于1992年，自創(chuàng)立以來致力于人類基因的搜尋和研究，至1999年6月止，HGS已發(fā)現(xiàn)及獲得6,450個人類基因和相關醫(yī)療應用的商業(yè)專利。目前，HGS公司已有三項基因藥物進入人體臨床實驗階段，分別為KGF-2、MPIF-1、和VEFG-2。其中的兩項(MPIF-1 及KGF-2)的作用為保護正常細胞，降低癌癥病患所受到化學治療的不適和排斥現(xiàn)象。 MPIF-1的全名為Myeloid Progenitor Inhibitory Factor-1，是一種具有保護造血細胞功能的蛋白質。 KGF-2的全名為Keratinocyte Growth Factor-2，主要功能是修補表皮細胞和粘膜層，有利于慢性或潰爛性傷口的愈合。第三種臨床用藥-VEGF-2的全名為Vascular Endothelial Growth Factor-2，具有在心臟和四肢血管再造的功能。對于VEGF-2的開發(fā)，目前HGS是以和Vascular Genetics Inc (血管基因公司)合作的形式進行。

人類基因組科學公司(HGS Inc.)的資金來源主要是由其商業(yè)投資者和數(shù)家大型藥廠所提供。至今，HGS公司已定期從多家生技藥商收取其基因專利使用權利金。因此與多家新興生技公司相較之下，其經(jīng)費來源相當穩(wěn)定。

人類基因科學公司的總部目前位于馬理蘭州的洛克維爾(Rockville)市， 現(xiàn)有原工327人。公司股票在拿斯達克(NASDAQ)店頭市場掛牌， 股名為"HGSI"。以新興公司集資能力而言，HGS公司表現(xiàn)相當優(yōu)秀。公司的總資產(chǎn)估計約8.5億美元，上市第一年的股價曾由15美元上升到超過200美元， 在人類基因組序碼被破解的熱潮時, 聚集了相當可觀的資本。


???

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

Late-Stage Products

We are poised for the market with a clinical pipeline that includes three novel products in late-stage development:

BENLYSTA? (belimumab) has successfully completed Phase 3 development in systemic lupus, and we expect the submission of marketing applications in the United States, Europe and other regions in the first half of 2010.
ZALBIN? (albinterferon alfa-2b) has successfully completed Phase 3 development in chronic hepatitis C. We have submitted a Biologics License Application to the FDA for ZALBIN in the United States, and we expect submission of marketing authorization applications soon in other regions of the world, beginning with Europe in fourth quarter 2009.
In May 2009, we filed a Biologics License Application for raxibacumab with FDA for inhalational anthrax.
We believe both BENLYSTA and ZALBIN have the therapeutic potential to change and save lives and, assuming regulatory approval, the commercial potential to become leading products in the marketplace. Each is being co-developed and commercialized in collaboration with a world leader in the pharmaceutical industry – GlaxoSmithKline (GSK) for BENLYSTA and Novartis for ZALBIN.

Raxibacumab is being developed under a contract with the U.S. Government and represents a new way to address the threat of inhalational anthrax. In April 2009, we completed the delivery of 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalational anthrax. In July 2009, we secured a new purchase order for 45,000 doses of raxibacumab to be delivered to the Stockpile over a three-year period beginning near the end of 2009.

Mid-Stage Pipeline

Right behind these three late-stage products is a high-potential mid-stage pipeline led by mapatumumab, our TRAIL receptor antibody for cancer. We also have substantial financial rights to a number of products in the GSK pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria? (albiglutide) in type 2 diabetes.

Manufacturing and Process Development

Our manufacturing and process development capability represents a significant strategic advantage. HGS is able to produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities – totaling approximately 400,000 square feet and offering both small-scale and large-scale production.

Strong Cash Position

Unlike many pre-commercial biopharmaceutical companies, HGS has built a strong cash position that allows us to focus on advancing our lead products toward commercialization as rapidly as possible, while at the same time investing in our early- and mid-stage pipeline. We are committed to achieving and sustaining growth well into the future.

?